Insider Transactions
| Date | Name | Title | Type | Shares Traded | Price Range |
|---|---|---|---|---|---|
| Jun 23, 2022 |
Chief Medical Officer
|
Chief Medical Officer | Open market or private sale of non-derivative or derivative security | 6,667 | $0.84 |
| Jun 23, 2022 |
Chief Medical Officer
|
Chief Medical Officer | Other acquisition or disposition | -- | -- |
| Jun 23, 2022 |
Chief Legal Officer
|
Chief Legal Officer | Other acquisition or disposition | -- | -- |
| Jun 23, 2022 |
Director, CEO & President
|
Director, CEO & President | Other acquisition or disposition | -- | -- |
| Jun 22, 2022 |
Chief Medical Officer
|
Chief Medical Officer | Open market or private sale of non-derivative or derivative security | 6,096 | $0.81 |
| Jun 21, 2022 |
Director
|
Director | Open market or private sale of non-derivative or derivative security | 4,283 | $0.79 |
| Jun 21, 2022 |
EVP & CFO
|
EVP & CFO | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 334,507 | -- |
| Jun 21, 2022 |
EVP & CFO
|
EVP & CFO | Open market or private sale of non-derivative or derivative security | 3,569 | $0.79 |
| Jun 21, 2022 |
EVP & CFO
|
EVP & CFO | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 1,515,957 | -- |
| Jun 21, 2022 |
Director
|
Director | Open market or private sale of non-derivative or derivative security | 5,711 | $0.79 |
| Jun 21, 2022 |
Chief Medical Officer
|
Chief Medical Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 405,040 | -- |
| Jun 21, 2022 |
Chief Medical Officer
|
Chief Medical Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 1,488,940 | -- |
| Jun 21, 2022 |
Chief Legal Officer
|
Chief Legal Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 246,085 | -- |
| Jun 21, 2022 |
Chief Legal Officer
|
Chief Legal Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 904,077 | -- |
| Jun 21, 2022 |
Director, CEO & President
|
Director, CEO & President | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 405,040 | -- |
| Jun 21, 2022 |
Director, CEO & President
|
Director, CEO & President | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 1,078,500 | -- |
| Jun 21, 2022 |
Director, CEO & President
|
Director, CEO & President | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 1,488,940 | -- |
| Jun 21, 2022 |
Former Director
|
Former Director | Open market or private sale of non-derivative or derivative security | 4,283 | $0.79 |
| Mar 25, 2022 |
Director
|
Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 4,759 | -- |
| Mar 25, 2022 |
Director
|
Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 22,601 | -- |
| Feb 24, 2022 |
Chief Legal Officer
|
Chief Legal Officer | Open market or private sale of non-derivative or derivative security | 15,031 | $0.64 |
| Feb 24, 2022 |
Chief Legal Officer
|
Chief Legal Officer | Other acquisition or disposition | -- | -- |
| Feb 23, 2022 |
Chief Legal Officer
|
Chief Legal Officer | Open market or private sale of non-derivative or derivative security | 13,513 | $0.70 |
| Feb 14, 2022 |
Director
|
Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 10,000 | $0.69 |
| Jun 23, 2021 |
Chief Medical Officer
|
Chief Medical Officer | Open market or private sale of non-derivative or derivative security | 5,000 | $4.00 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.